Replies to post #187898 on Biotech Values

[DewDiligence]

ENTA/MRK—On CNBC today they were speaking of the Merck hep c data being presented at liver conference in April and if shows a 95+ success rate at 12 weeks can capture 20% of mkt. Can you either comment or refer me back to a prior post in which you spoke to that?

Please see:

#msg-106879491 MRK’s phase-3 trials in specialized (and somewhat unusual) patient groups
#msg-106892976 Musings on impetus for these specialized trials
#msg-106754175 Possible safety signal
#msg-106759910 Musings on MRK’s phase-3 program in general
#msg-106760354 Ditto
#msg-100393061 Phase-2 data for 2-DAA regimen